The application of artificial intelligence in the medical field is moving from auxiliary tools to core diagnostic and treatment processes. In the first half of 2026, the global AI healthcare market has exceeded $80 billion, with medical imaging AI being the most mature niche. From detecting pulmonary nodules to screening for retinal lesions, the diagnostic accuracy of AI models has surpassed that of experienced radiologists in multiple clinical trials.
The AI diagnostic system with computer vision as its core can automatically analyze CT images within seconds, mark suspicious lesion areas, and increase the detection rate to over 98%. The breast cancer screening AI developed by Google Health has achieved significant results in reducing the false positive rate by 5.7% and the false negative rate by 9.4% in the real clinical environment, greatly reducing the workload of doctors.
The intelligent consultation system is another cutting-edge direction. A medical AI assistant based on a big language model can understand the symptoms described by patients, combine electronic medical record data, and provide preliminary diagnostic recommendations and medical guidance. Peking Union Medical College Hospital began piloting an AI assisted pre consultation system as early as 2023, reducing the average waiting time for patients by 40%.
However, AI healthcare also faces challenges such as data privacy, algorithmic bias, and regulatory compliance. The EU's Artificial Intelligence Act classifies medical AI as a high-risk application, requiring strict transparency and interpretability standards. In the future, AI will not replace doctors, but doctors who make good use of AI will undoubtedly replace their peers who are not good at using AI. The healthy development of AI healthcare requires finding a balance between technological innovation and ethical standards. [Reference source] Google Health official blog, EU AI Act official text